Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections

Journal of Infection and Chemotherapy

Volumn 19, Issue 3, 2013, Pages 447-455

  Aikawa, Naoki ^a   Kusachi, Shinya ^b   Mikamo, Hiroshige ^c   Takesue, Yoshio ^d   Watanabe, Shinichi ^e   Tanaka, Yoshiyuki ^f   Morita, Akiko ^f   Tsumori, Keiko ^f   Kato, Yoshiaki ^f   Yoshinari, Tomoko ^f  

^a KEIO UNIVERSITY   (Japan)

^b TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^c AICHI MEDICAL UNIVERSITY   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Merck Sharp Dohm Res Labs Japan   (Japan)

Author keywords

Daptomycin; MRSA; Skin infection; Soft tissue infection; SSTI; Vancomycin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIINFECTIVE AGENT; ARBECACIN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; DAPTOMYCIN; LINEZOLID; OXACILLIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLACTIC SHOCK; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; JAPAN; JAPANESE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84879248599     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0501-9     Document Type: Article

References (20)

1. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:2538-44.
2. Baltz RH. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol. 2009;13:144-51.
3. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010;65(suppl 3):iii35-44
4. Stefani S, Goglio A. Methicillin-resistant Staphylococcus aureus: related infections and antibiotic resistance. Int J Infect Dis. 2010;14(suppl 4):S19-22.
5. Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother. 2002;49:467-70.
6. Sader HS, Watters AA, Fritsche TR, Jones RN. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis. 2007;7:29.
7. Tsuji BT, Rybak MJ, Cheung CM, Amjad M, Kaatz GW. Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents. Diagn Microbiol Infect Dis. 2007;58:41-7.
8. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673-81.
9. Goto H, Shimada K, Ikemoto H, Oguri T. Antimicrobial susceptibility of pathogens isolated from more than 10,000 patients with infectious respiratory diseases: a 25-year longitudinal study. J Infect Chemother. 2009;15:347-60.
10. Kunishima H, Yamamoto N, Kobayashi T, Minegishi M, Nakajima S, Chiba J, et al. Methicillin-resistant Staphylococcus aureus in a Japanese community hospital: 5-year experience. J Infect Chemother. 2010;16:414-7.
11. Hasegawa S, Miki M, Wan K, Aoki I. A phase I study in Japanese healthy subjects with single and multiple intravenous dose of daptomycin (MK-3009). Antibiot Chemother. 2011;27:135-48.
12. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49:507-14.
13. Minson Q, Gentry CA. Analysis of linezolid-associated hematologic toxicities in a large veterans affairs medical center. Pharmacotherapy. 2010;30:895-903.
14. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-65.
15. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50:1568-74.
16. Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49:177-80.
17. Sader HS, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis. 2009;65:158-62.
18. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann Pharmacother. 2009;43:1211-9.
19. Mermel LA, Allon M, Bouza E, Craven AE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;49:1-45.
20. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-55.